


# Stabilis



## Mycophenolate mofetil



Noms commerciaux

Cellcept	Allemagne, Australie, Autriche, Canada, Colombie, Danemark, Espagne, Etats Unis d'Amérique, Finlande, France, Grande Bretagne, Grèce, Hongrie, Irlande, Italie, Japon, Luxembourg, Mexique, Norvège, Nouvelle Zélande, Pays bas, Pologne, Portugal, Suède, Suisse
Micofenolato de mofetilo	Espagne
Mycophenolate mofetil	Allemagne, Belgique, Grande Bretagne



### Stabilité des solutions

PVC	◆	1 & 10 mg/ml	25°C	?	7	☾		1981
PVC	◆	1 & 10 mg/ml	4°C	?	7	☾		1981
PP	◆	1 mg/ml	-15 >> -25°C		35	☾		4299
PP	◆	1 mg/ml	2-8°C		35	☾		4299
PP	◆	1 mg/ml	23-27°C		14	☾		4299
PP	◆	10 mg/ml	-15 >> -25°C		35	☾		4299
PP	◆	10 mg/ml	2-8°C		35	☾		4299
PP	◆	10 mg/ml	23-27°C		14	☾		4299
PP	◆	4 mg/ml	-15 >> -25°C		35	☾		4299
PP	◆	4 mg/ml	2-8°C		35	☾		4299
PP	◆	4 mg/ml	23-27°C		14	☾		4299



## Facteur influençant la stabilité

				1981
				1981



## Compatibilités

		Mycophenolate mofetil : 6 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Mycophenolate mofetil		1981
		Mycophenolate mofetil : 6 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Mycophenolate mofetil : 10 mg/ml Atenolol : 0,1 mg/ml		4698
		Mycophenolate mofetil : 6 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Mycophenolate mofetil : 5,9 mg/ml Cefepime dihydrochloride : 20 mg/ml		2192
		Mycophenolate mofetil : 6 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Mycophenolate mofetil : 5,9 mg/ml Ciclosporin : 1 mg/ml		2192
		Mycophenolate mofetil : 10 mg/ml Clonidine hydrochloride : 0,0125 mg/ml		4698
		Mycophenolate mofetil : 11.9 mg/ml Defibrotide : 8 mg/ml		3728
		Mycophenolate mofetil : 5,9 mg/ml Dopamine hydrochloride : 4 mg/ml		2192
		Mycophenolate mofetil : 6 mg/ml Fosfomycin : 30 mg/ml		4055
		Mycophenolate mofetil : 6 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Mycophenolate mofetil : 6 mg/ml Micafungin : 1.5 mg/ml		2108
		Mycophenolate mofetil : 5,9 mg/ml Norepinephrine bitartrate : 1 mg/ml		2192
		Mycophenolate mofetil : 5,9 mg/ml Tacrolimus : 20 µg/ml		2192
		Mycophenolate mofetil : 5,9 mg/ml Vancomycin hydrochloride : 10 mg/ml		2192




## Bibliographie

	Type	Source
1981	Revue	Certain E, Beteta F, Goudou-Sinha C, Darbord JC, Prognon P, Jacquot C. Stability of i.v. mycophenolate mofetil in 5% dextrose injection in polyvinyl chloride infusion bags. Am J Health-Syst Pharm 2002 ; 59: 2434-2439.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2192	Revue	Cochran BG, Sowinski KM, Fausel C, Overholser BR. Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs. Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3728	Revue	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolin/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavuconazole sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4299	Revue	Ezquer-Garin C, Ferriols-Lisart R, Alos-Alminana M. Stability of mycophenolate mofetil in polypropylene 5% dextrose infusion bags and chemical compatibility associated with the use of the EQUASHIELD® closed-system transfer device. Biomed Chromatogr 2019 ; 33, 7: e4529.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4698	Revue	Ayari G, D&#39;Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022

# Stabilis



## Mycophenolate mofetil



### Stabilité des préparations

		6000 mg Cellcept® Aspartam 180 mg Arôme cerise 240 mg OraPlus® >> 60 ml PH= 6	2-8°C		120			2414
		6000 mg Cellcept® Eau purifiée >> Sirop de cerise >> 60 ml	2-8°C		121			2448
		6000 mg Cellcept® Aspartam 180 mg Arôme cerise 240 mg OraPlus® >> 60 ml PH= 6	23-25°C		28			2414
		6000 mg Cellcept® Eau purifiée >> Sirop de cerise >> 60 ml	23-25°C		121			2448
		2500 mg Cellcept® OraPlus® / OraSweet® (1:1) >> 50 ml	2-8°C		90			2857
		5000 mg Cellcept® OraPlus® / OraSweet® (1:1) >> 50 ml	2-8°C		90			2857
		2500 mg Cellcept® OraPlus® / OraSweet® (1:1) >> 50 ml	2-8°C		90			2857
		5000 mg Cellcept® OraPlus® / OraSweet® (1:1) >> 50 ml	2-8°C		90			2857
		1500 mg Celcept® OraPlus® 7.5 ml Sirop de cerise >> 30 ml	2-6°C		210			2543
		1500 mg Celcept® OraPlus® 7.5 ml Sirop de cerise >> 30 ml	21-28°C		28			2543



## Bibliographie

	Type	Source
2414	Revue	Swenson CF, Dentinger PJ, Anaizi NH. Stability of mycophenolate mofetil in an extemporaneously compounded sugar-free oral liquid Am J Health-Syst Pharm 1999 ; 56: 2224-2226.
2448	Revue	Anaizi NH, Swenson CF, Dentinger PJ. Stability of mycophenolate mofetil in an extemporaneously compounded oral liquid Am J Health-Syst Pharm 1998 ; 55: 926-929.
2543	Revue	Venkataramanan R, McCombs, JR, Zuckerman S, McGhee B, Pisupati J, Dice JE. Stability of mycophenolate mofetil as an extemporaneous suspension.  Ann Pharmacotherapy 1998 ;32:755-757.
2857	Revue	Ensom MHH, Decarle D. Stability of Mycophenolate Mofetil in a 1:1 Mixture of Ora-Sweet and Ora-Plus. Can J Hosp Pharm 2002 ; 55, 1: 63-65.



# Dictionnaire

 Immunosuppresseur	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Polyvinyl chlorure
 Glucose 5%	 Non précisée
 Jour	 Polypropylène
 A l'abri de la lumière	 Facteur influençant la stabilité
 Lumière	 Provoque
 Dégradation	 Solvant
 Chlorure de sodium 0,9%	 Précipitation
 Compatibilités	 Molécule
 Précipitation immédiate	 Incompatible
 NaCl 0,9% ou glucose 5%	 Compatible
 Dégagement gazeux	 Turbidité immédiate
 Voie d'administration	 Perfusion intraveineuse
 Bibliographie	 Solution buvable
 Stabilité des préparations	 Origine
 Excipient	 Flacon plastique
 Gélules	 Non précisé
 Dictionnaire	